BioAegis Therapeutics to Sponsor a Webinar, Below the Eyes of the Hippopotamus: The Expanding Spectrum of Auto- and Hyper- Inflammatory Diseases
May 10, 2023 07:20 ET
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., May 10, 2023 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc., a clinical-stage company developing novel therapies for inflammatory diseases through a portfolio built around...
Pan-Biome Pharmaceuticals, a startup focused on age-related diseases and increasing human healthspan, reports positive results in a preclinical trial of colitis
April 25, 2023 10:00 ET
|
Pan-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, April 25, 2023 (GLOBE NEWSWIRE) -- Pan-Biome Pharmaceuticals, Inc, a Vancouver based preclinical biopharmaceutical company focused on age-related diseases and extending...
BioAegis Therapeutics Announces Two Studies Exploring the Role of ‘Inflammation Regulator’ Gelsolin in Type 2 Diabetes
April 13, 2023 14:03 ET
|
BioAegis Therapeutics
Gelsolin decreased microparticle-driven inflammation and mitigated activation of the NLRP3 inflammasome in type 2 diabetes. Low levels of gelsolin identified in individuals with type 2 diabetes...
Landmark Publication Underscores Robust Ability of CytoSorb to Reduce Cytokine Storm during Systemic Hyperinflammation
March 29, 2023 08:30 ET
|
CytoSorbents
PRINCETON, N.J., March 29, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
Cardiometabolic Health Congress Announces Spring Conference Focused on Inflammation and Cardiometabolic Disease
March 16, 2023 08:00 ET
|
Cardiometabolic Health Congress
Boca Raton, FL, March 16, 2023 (GLOBE NEWSWIRE) -- In line with its mission to deliver quality medical education to combat the spectrum of cardiometabolic diseases, CMHC joins forces with the...
AB2 Bio Completes Enrolment in Pivotal Phase 3 Trial of Tadekinig alfa to Treat Primary Monogenic IL-18 Driven HLH
March 07, 2023 03:00 ET
|
AB2 Bio Ltd
Topline pivotal Phase 3 results expected during second half of 2023Potential new treatment option in ultra-rare, life-threatening, primarily pediatric disease with no approved therapies Lausanne...
Evelo Biosciences Reports that EDP2939, its First Oral Extracellular Vesicle Product Candidate, Commenced Dosing in a Phase 2 Psoriasis Trial
February 27, 2023 06:00 ET
|
Evelo Biosciences, Inc.
– Completed first blinded, placebo-controlled cohort in human volunteers with no safety or tolerability concerns – – Dosing in EDP2939 Phase 2 trial in patients with moderate psoriasis has been...
Two Nutrients Help Relieve Pain from Inflammation in Virtual Clinical Research Study
February 23, 2023 11:11 ET
|
Life Extension
For Lauderdale, FL, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Is mild discomfort when walking, standing up or doing day-to-day activities a necessary evil of getting older? Indeed, these pangs, generally...
Insights on the Allergy Immunotherapies Global Market to 2028: Rising Awareness of Allergy Immunotherapies, Elevating Income Levels and Increasing Healthcare Expenditure Drives Growth
February 21, 2023 13:18 ET
|
Research and Markets
Dublin, Feb. 21, 2023 (GLOBE NEWSWIRE) -- The "Allergy Immunotherapies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028" report has been added to ...
BioAegis Therapeutics Announces FDA Clearance of IND for its ‘Inflammation Regulator Protein,’ Gelsolin, for the Treatment of ARDS
January 26, 2023 14:05 ET
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., Jan. 26, 2023 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc., a clinical-stage company developing therapies for inflammatory diseases through a portfolio built around plasma...